Navigation Links
JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
Date:7/29/2009

A novel anticancer agent, consisting of a monoclonal antibody linked to a chemotherapy drug, showed substantial antitumor activity in ovarian cancer cell lines and in mice, according to a study published online July 29 in the Journal of the National Cancer Institute.

The agent, known as an immunoconjugate, targets a protein, EphA2, which is overexpressed in many human cancers but is absent or expressed at low levels in normal tissues.

Anil K. Sood, M.D., of The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues tested the immunoconjugate in ovarian cancer cell lines, where it bound to cells with high levels of EphA2 but not to those without the protein. In mice, the EphA2 immunoconjugate inhibited tumor growth by 85%󈟎% compared with that in mice treated with a control immunoconjugate, a highly statistically significant difference. In cell lines, its antitumor effects were also statistically significantly related to decreased proliferation and increased apoptosis of tumor cells.

Chemotherapy drugs typically affect both tumor and normal tissues, which can result in side effects. The immunoconjugate tested by the in this study allows for highly selective delivery of chemotherapy. "In summary," the authors write, "the findings herein provide a novel EphA2-targeted immunoconjugate with potent antitumor activity in ovarian carcinoma. Further preclinical and clinical developmentappears to be warranted."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
7. Antibody Helps Repair MS Nerve Damage
8. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
9. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
10. Antibody responses in patients with Lyme arthritis
11. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
(Date:7/12/2014)... 2014 Fresh off their respective performances in ... meet on September 5th at Sun Life Stadium in an ... some of the brightest stars in the world of football ... will be treated to some of the best talent in ... as the third best team in the world according to ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... Demand Response Management Systems is a ... reducing the imbalance between energy supply and demand. With ... rolled out (due to increasing pressure on the grid) ... in controlling residential appliances and thermostats for load reduction. ... American region, and with government mandates and benefits for ...
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
Breaking Medicine News(10 mins):Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
... , SEATTLE, June 24 Lightspeed Design, Inc. announces ... software for state-of-the-art capture and playback of HD 3D ... hundreds of professional clients in corporate, entertainment, medical and ... into the new DepthQ(R) family of stereoscopic software -- ...
... , Pig jaw workshop gives attendees hands-on experience , ... RIEMSER , a leading manufacturer of bone tissue regeneration ... grafting workshop to be held in Chicago Friday, July 24th ... step-by-step instructions in site preservation, information on bone grafting materials ...
... doubt on notion of moms, unconditional love , ... likely than men to look away from less-than-cute babies, ... a mother,s unconditional love. , The findings might reflect ... healthy offspring, suggest the researchers, from Harvard-affiliated McLean Hospital ...
... OPEN NEXT SPRING IN HOUSTON METROPOLITAN AREA ... Living, Inc. (OTC Bulletin Board: TCSR), which develops, manages and ... a funding agreement with a national lender for the development ... metropolitan area. Funding for Trinity Terrace , an ...
... of Phosphatidylserine-Targeting Antibodies to Image Solid Tumors and Other Malignancies ... Showing Utility of PS-Targeting Antibodies for the Molecular Imaging of ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent ...
... Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use ... a New Report from AMR and Decision Resources , ... /PRNewswire/ -- Arlington Medical Resources (AMR) and ... oral formulation is a leading drug attribute that surveyed ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:RIEMSER Announces Upcoming Chicago Bone Grafting Workshop 2Health News:Women More Likely Than Men to Reject Unattractive Babies 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fourth Senior Living Facility 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 4Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 Mylan Inc. (Nasdaq: MYL ) ... announced refinancing of its existing secured credit facility. The ... upsized from the originally planned $2.25 billion and comprises ... billion Term Loan A facility. The proceeds were used ...
... CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 University ... School of Medicine and Lentigen Corporation announced today the ... LG631 gene therapy for the protection of hematopoietic stem ... with Temodar.   Approximately 17,000 Americans are ...
Cached Medicine Technology:Mylan Successfully Upsizes and Completes Refinancing of Credit Facility 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
Medicine Products: